Introduction

- Restenosis is the Achilles heel of vascular intervention
- Much of the clinical and research activity over the last 20 years has been focused on preventing restenosis
- DEB = philosophy to leave nothing behind
- This symposium will present a new solution based on unique technologies, the SELUTION SLR™
  - From Bench-to-Bed
  - Sirolimus in DEB Technology
  - Importance of sustained release
  - Different indications for sirolimus eluting balloons
  - Which patients will potentially benefit from such breakthrough technology
Agenda

A Breakthrough in Drug-Eluting Balloon Technology
MedAlliance sponsored Symposium

Moderators: M. Brodmann, P. Gaines

➢ Welcome and Introduction
  M. Brodmann

➢ Importance of sustained drug release in DEB: Insights into preclinical data for the SELUTION SLR™
  A. Finn

➢ Sustained Limus release translating into sustained clinical outcomes: SELUTION SFA – 2-year results
  T. Zeller

➢ SELUTION SLR™ in clinical practice: Angio case examples
  U. Beschorner

➢ How low can you go? SELUTION SLR™ below-the-knee and in tibial arteries – first experience
  T. Y. Tang

➢ Next Steps and Adjourn
  P. Gaines